NCT03088267View on ClinicalTrials.gov

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 11, 2017

Primary Completion Date

February 25, 2017

Study Completion Date

October 30, 2017

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

amphetamine extended-release oral suspension, 2.5 mg/mL

5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

DRUG

Placebo extended-release oral suspension

6, 7 or 8 mL PO

Trial Locations (1)

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

All Listed Sponsors
lead

Tris Pharma, Inc.

INDUSTRY

NCT03088267 - Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study | Biotech Hunter | Biotech Hunter